Knowledge of Pregnant Women Concerning Pertussis, Vaccination Against Pertussis and Cocooning Strategy

NCT ID: NCT06114160

Last Updated: 2023-11-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-12-01

Study Completion Date

2024-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In France, it has been recommended since 2022 that pregnant women be vaccinated against pertussis from 20 to 36 weeks' gestation.

This vaccination schedule is inspired by the Anglo-Saxon model and studies showing the effectiveness of this practice.

The aim of this vaccine is to protect the newborn by transferring antibodies from the fetus to the placenta, because Pertussis is a particularly serious disease in newborns.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim is to describe pregnant women's knowledge concerning pertussis, vaccination against pertussis during pregnancy and the cocooning strategy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pertussis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

pregnant women

Pregnant women between 20 and 41 weeks of amenorrhoea, primiparous.

Data collection

Intervention Type OTHER

Data collection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Data collection

Data collection

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pregnant between 20 and 41 weeks of amenorrhea
* Primiparous
* aged more than 18
* Agreed to participate in the study

Exclusion Criteria

* Multiparous
* Protected by law (guardianship, guardianship, safeguarding of justice)
* Not agreed to participate in this study
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Université de Reims Champagne-Ardenne

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pilet Caroline, midwife

Role: PRINCIPAL_INVESTIGATOR

CHU de Reims

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Barbe Coralie, DR

Role: CONTACT

0326913665 ext. +33

CURRS CURRS

Role: CONTACT

0326918822 ext. +33

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023_RIPH_015_Coqueluche-Vac

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Gambia Pertussis Study (GaPs)
NCT03606096 UNKNOWN PHASE4
Boostrix® Pregnancy Registry
NCT02096276 COMPLETED